Through its microbial testing kits and regenerative medicine solutions, Shimadzu Diagnostics is helping to tackle the greatest global health challenges.
Following its establishment in 1935, Nissui Pharmaceutical sourced marine-based ingredients for medicinal and pharmaceutical purposes. Today, the company – which was renamed Shimadzu Diagnostics Corporation in April following its 100% takeover by Shimadzu Corporation – is a leader in the field of microbial testing kits and regenerative medicine solutions.
The emergence of new strains of bacteria is one of the most serious global health challenges. To tackle this issue, tracing where the resistant strains come from and identifying the root causes for resistance is of paramount importance. In response, Nissui developed Raisus S4, a fully automated rapid bacteria identification and antimicrobial susceptibility testing instrument using digital detection technology.
Another of the company’s flagship microbial testing kits is Compact Dry, a ready-to-use culture media that is used in the detection of bacteria strains and the potential causes for food poisoning. “While other culture media require chilling between 2-5°C, CompactDry is a dry medium that can be transported without such precautions,” explains company president Tokuya Ono.
With Japan leading the way in regenerative medicine, Shimadzu Diagnostics is supporting the fast-growing medical field with cell culture medium and testing solutions, including HYDROX, a three-dimensional cell culture substrate that allows the growth of different types of cells, and MSF-BM, a high-quality cell culture medium. “Since the cell culture business, particularly culture media and reagents, is part of our rich know-how, our strategy is to provide custom-made solutions in this field,” says Mr. Ono.